menarini.co.uk Menarini Pharma UK - Menarini Pharma UK

menarini.co.uk
Title: Menarini Pharma UK - Menarini Pharma UK
Keywords: MenariniGroup, Menarini Pharma UK
Description: Menarini Biotech has been a Centre of Excellence in Italy for Biotechnology that has years of experience in developing and manufacturing bio-pharmaceuticals for the Menarini Group.
menarini.co.uk is ranked 20905747 in the world (amongst the 40 million domains). A low-numbered rank means that this website gets lots of visitors. This site is relatively popular among users in the united states. It gets 50% of its traffic from the united states .This site is estimated to be worth $4,919. This site has a low Pagerank(0/10). It has 1 backlinks. menarini.co.uk has 43% seo score.

menarini.co.uk Information

Website / Domain: menarini.co.uk
Website IP Address: 217.29.168.146
Domain DNS Server: ns1.register.it,ns2.register.it

menarini.co.uk Rank

Alexa Rank: 20905747
Google Page Rank: 0/10 (Google Pagerank Has Been Closed)

menarini.co.uk Traffic & Earnings

Purchase/Sale Value: $4,919
Daily Revenue: $13
Monthly Revenue $404
Yearly Revenue: $4,919
Daily Unique Visitors 1,240
Monthly Unique Visitors: 37,200
Yearly Unique Visitors: 452,600

menarini.co.uk WebSite Httpheader

StatusCode 200
Cache-Control no-cache, must-revalidate
Content-Type text/html; charset=utf-8
Date Mon, 01 Aug 2016 06:16:23 GMT
Server Apache

menarini.co.uk Keywords accounting

Keyword Count Percentage
MenariniGroup 0 0.00%
Menarini Pharma UK 2 2.32%

menarini.co.uk Traffic Sources Chart

menarini.co.uk Similar Website

Domain Site Title

menarini.co.uk Alexa Rank History Chart

menarini.co.uk aleax

menarini.co.uk Html To Plain Text

Menarini Pharma UK - Menarini Pharma UK News and Press Release The Menarini Group: new molecule against lymphomas and solid tumors, 25th November 2014 Researchers present a new potential "weapon" for the destruction of tumour cells. Its name is MEN1309 and this new antibody is currently being studied by researchers at Menarini and Oxford Bio Therapeutics (OBT) against Non Hodgkin's lymphomas and solid tumours. Menarini: one of top ten most "patient friendly" companies, 20th June 2014 Leukemia: a refuse-collecting drug which can reduce the risks posed by chemotherapy, 11th February 2014 OXFORD, UK and BERLIN CHEMIE/MENARINI, GERMANY, 9th December 2013 Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia as First Clinical Development Candidate in $1 Billion Oncology Investment Alliance MOUNTAIN VIEW, Calif., July 9, 2013 - VIVUS ANNOUNCES AVANAFIL PARTNERSHIP WITH MENARINI Menarini to launch and market SPEDRA (Avanafil) in 40 countries, UK included Oxford, UK and Florence, Italy, 8th March 2013 Innovative cancer partnership gains Menarini Group and Oxford BioTherapeutics industry award nomination Oxford, UK and Florence, Italy, 29thOctober 2012 Menarini Group and Oxford BioTherapeutics Sign Major Strategic Collaboration for the Clinical Development and Manufacture of a Portfolio of Novel Antibody-Based Cancer Drugs Company profile History Products Worldwide Research & Development Manufacturing Job opportunities Company Disclosures Our Ethical Code Contact Us terms and conditions | privacy policy | site map English V.A.T. 851966002

menarini.co.uk Whois

Domain Name: MENARINI.CO.UK